Johannesburg - Aspen Pharmacare Holdings
[JSE:APN] said on Thursday that it expected its diluted normalised headline earnings per share from continuing operations to rise between 18% and 24% in the year ended June‚ from the previous comparable period.
Headline earnings per share are expected to climb between 21% and 27%‚ from the same period a year ago‚ while earnings per share are expected to between 4% and 10% higher.
The growth in earnings per share has been reduced as a result of capital profits on the disposal of discontinued businesses and products in the present year being lower than in the prior year‚ it said.